STRATEC SE

M&A Activity • Aug 26, 2002

News Details

Ad-hoc | 26 August 2002 12:32

Stratec Biomedical Sys. english

Stratec and Chiron announce completion of a development and supply agreement Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Stratec and Chiron announce completion of a development and supply agreement According to § 15 WpHG, the Board of Management of STRATEC Biomedical Systems AG announces the successful completion of a development and supply agreement with Chiron Corporation. The Agreement between Chiron and Stratec includes the development of new instrumentation platforms by Stratec for Chiron. Following the successful instrumentation development, intended as an ongoing agreement, both parties have agreed to a subsequent supply contract covering the purchase of the instruments. For competitive reasons the two companies agreed to not disclose the specifics regarding the contract volume or technology. end of ad-hoc-announcement (c)DGAP 26.08.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: About Chiron Corporation Chiron Corporation, headquartered in Emeryville, California, is a global pharmaceutical company that leverages a diverse business model to development and commercializes high-value products that make a difference in people’s lives. The company has a strategic focus on cancer and infectious disease. It applies its advanced understanding of the biology of cancer and infectious disease to develop products from its platforms in proteins, small molecules, and vaccines. The company commercializes its products through three business units: BioPharmaceuticals, Vaccines and Blood Testing. For more information, visit the company’s website at www.chiron.com. About Stratec Based on its own patent-protected technologies STRATEC Biomedical Systems AG (SIN: 728900 / ISIN: DE0007289001 http://www.stratec-biomedical.de) designs and manufactures fully automated systems for partners in clinical diagnostics and biotechnology. These partners sell the analyzers to laboratories and research institutes worldwide as system solutions together with their reagents. Following its business model, STRATEC Biomedical Systems AG maintains ongoing negotiations with major diagnostics and life-science companies. The successful conclusion of contracts and completion of the design processes could lead to further significant growth of the company. For further information, please contact us at +49 (0)7082 – 791633 or ir@stratec-biomedical.de. ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Stuttgart und Frankfurt (SMAX); Freiverkehr in Berlin, Düsseldorf und Hamburg 261232 Aug 02